AstraZeneca plc (AZN) Ordinary US$0.25
- Add to watchlist
- Create an alert
- This stock can be held in a
12,114.00p
12,269.67p
12,266.00p
£189.75 bn
12,170.00p
12,114.00p
9,461.00p
39.73
108.00p (0.90%) Previous:
108.00p
187,210
1.86%
200
Performance
1 week 1W | 7.21% | 1 year 1Y | 3.61% |
---|---|---|---|
1 month 1M | 13.97% | 2 years 2Y | 13.87% |
3 months 3M | 16.68% | 3 years 3Y | 57.74% |
6 months 6M | 17.74% | 5 years 5Y | 115.63% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 45,811.00 | 44,351.00 |
Profit before tax ($m) | 6,899.00 | 2,501.00 |
Adjusted EPS (¢): | 384.00 | 212.00 |
P/E ratio | 34.60 | 66.30 |
PEG | 0.40 | n/a |
EPS growth (%) | 81.00 | 2,550.00 |
Values are quoted in the stock's local currency: US dollar
All fundamental dataRecent dividends paid or declared by AstraZeneca plc:
Type | Ex-div date | Payment date | Amount |
---|---|---|---|
2nd interim | 22/02/2024 | 25/03/2024 | 197.00¢ |
1st interim | 10/08/2023 | 11/09/2023 | 93.00¢ |
2nd interim | 23/02/2023 | 27/03/2023 | 197.00¢ |
1st interim | 11/08/2022 | 12/09/2022 | 93.00¢ |
2nd interim | 24/02/2022 | 28/03/2022 | 197.00¢ |
This data is provided by Digital Look. HL accepts no responsibility for its accuracy and you should independently check data before making any investment decision.
Full dividend historyFive years' total annual AstraZeneca plc dividends:
Financial year end |
Dividend yield |
Dividend cover |
Total dividend paid |
---|---|---|---|
31/12/2023 | 2.20% | 1.32 | $2.90 |
31/12/2022 | 2.10% | 0.73 | $2.90 |
31/12/2021 | 2.60% | 0.03 | $2.87 |
31/12/2020 | 3.00% | 0.87 | $2.80 |
31/12/2019 | 2.90% | 0.37 | $2.80 |
All dividend data is calculated excluding any special dividends. Historical dividends may be adjusted to reflect any subsequent rights issues and corporate actions.
Full dividend historyReady to invest?
Important Documents
There are no documents available for this stock.
-
AstraZeneca reports positive results from blood cancer drug trial
2 May 2024 07:45
-
AstraZeneca makes progress with two breast cancer treatments
29 April 2024 07:24
-
London close: Stocks finish mixed as US GDP growth slows
25 April 2024 15:14
-
Calquence combination improved PFS in 1L MCL
2 May 2024 07:00
-
Total Voting Rights
1 May 2024 15:00
-
Truqap recommended for EU breast cancer approval
29 April 2024 07:05
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.